These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 23943214)

  • 21. Duration of clopidogrel therapy with drug-eluting stents.
    Rennings AJ; Schouwenberg BJ; van Onzenoort HA
    N Engl J Med; 2010 Jul; 363(5):489; author reply 490. PubMed ID: 20830829
    [No Abstract]   [Full Text] [Related]  

  • 22. Associations of CYP3A4, NR1I2, CYP2C19 and P2RY12 polymorphisms with clopidogrel resistance in Chinese patients with ischemic stroke.
    Liu R; Zhou ZY; Chen YB; Li JL; Yu WB; Chen XM; Zhao M; Zhao YQ; Cai YF; Jin J; Huang M
    Acta Pharmacol Sin; 2016 Jul; 37(7):882-8. PubMed ID: 27133299
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The effect of the CYP 2C19*2 polymorphism on stroke care.
    Nyírő G; Inczédy-Farkas G; Reményi V; Gál A; Pál Z; Molnár MJ
    Acta Physiol Hung; 2012 Mar; 99(1):33-9. PubMed ID: 22425806
    [TBL] [Abstract][Full Text] [Related]  

  • 24. CRISPLD1 rs12115090 polymorphisms alters antiplatelet potency of clopidogrel in coronary artery disease patients in Chinese Han.
    Wang JY; Zhang YJ; Li H; Hu XL; Li MP; Song PY; Ma QL; Peng LM; Chen XP
    Gene; 2018 Dec; 678():226-232. PubMed ID: 30096456
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Impact of CYP2C19 Polymorphisms on Clinical Outcomes and Antiplatelet Potency of Clopidogrel in Caucasian Poststroke Survivors.
    Tomek A; Matʼoška V; Frýdmanová A; Magerová H; Šrámek M; Paulasova-Schwabová J; Růžičková T; Janský P; Šarbochová I; Hadačová I; Kaplan V; Lacinová Z; Táborský L; Serebruany V
    Am J Ther; 2018; 25(2):e202-e212. PubMed ID: 29509167
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Influence of CYP2C19 loss-of-function variants on the antiplatelet effects and cardiovascular events in clopidogrel-treated Chinese patients undergoing percutaneous coronary intervention.
    Zou JJ; Xie HG; Chen SL; Tan J; Lin L; Zhao YY; Xu HM; Lin S; Zhang J; Wang GJ
    Eur J Clin Pharmacol; 2013 Apr; 69(4):771-7. PubMed ID: 23001453
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Genetic polymorphisms and drug interactions leading to clopidogrel resistance: why the Asian population requires special attention.
    Hasan MS; Basri HB; Hin LP; Stanslas J
    Int J Neurosci; 2013 Mar; 123(3):143-54. PubMed ID: 23110469
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The impact of genetic polymorphisms of P2Y12, CYP3A5 and CYP2C19 on clopidogrel response variability in Iranian patients.
    Namazi S; Kojuri J; Khalili A; Azarpira N
    Biochem Pharmacol; 2012 Apr; 83(7):903-8. PubMed ID: 22265638
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cytochrome P450 2C19 loss-of-function polymorphism, but not CYP3A4 IVS10 + 12G/A and P2Y12 T744C polymorphisms, is associated with response variability to dual antiplatelet treatment in high-risk vascular patients.
    Giusti B; Gori AM; Marcucci R; Saracini C; Sestini I; Paniccia R; Valente S; Antoniucci D; Abbate R; Gensini GF
    Pharmacogenet Genomics; 2007 Dec; 17(12):1057-64. PubMed ID: 18004210
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Personalised antiplatelet therapy: are we ready for prime time? Data from China.
    Li J; Huo Y
    EuroIntervention; 2013 Jul; 9(3):296-8. PubMed ID: 23872644
    [No Abstract]   [Full Text] [Related]  

  • 31. Dual therapy with clopidogrel and aspirin prevents early neurological deterioration in ischemic stroke patients carrying CYP2C19*2 reduced-function alleles.
    Lin J; Han Z; Wang C; Yi X; Chai Z; Zhou Q; Huang R
    Eur J Clin Pharmacol; 2018 Sep; 74(9):1131-1140. PubMed ID: 29804161
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Polymorphisms of MDR1, CYP2C19 and P2Y12 genes in Indian population: effects on clopidogrel response.
    Shalia KK; Shah VK; Pawar P; Divekar SS; Payannavar S
    Indian Heart J; 2013; 65(2):158-67. PubMed ID: 23647895
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effects of CYP2C19 variant alleles on postclopidogrel platelet reactivity and clinical outcomes in an actual clinical setting in China.
    Wu H; Qian J; Xu J; Sun A; Sun W; Wang Q; Ge J
    Pharmacogenet Genomics; 2012 Dec; 22(12):887-90. PubMed ID: 22990067
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effect of CYP2C19*2 and *3 loss-of-function alleles on platelet reactivity and adverse clinical events in East Asian acute myocardial infarction survivors treated with clopidogrel and aspirin.
    Jeong YH; Tantry US; Kim IS; Koh JS; Kwon TJ; Park Y; Hwang SJ; Bliden KP; Kwak CH; Hwang JY; Gurbel PA
    Circ Cardiovasc Interv; 2011 Dec; 4(6):585-94. PubMed ID: 22045970
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Impact of CYP2C19 polymorphisms on the antiplatelet effect of clopidogrel in an actual clinical setting in Japan.
    Jinnai T; Horiuchi H; Makiyama T; Tazaki J; Tada T; Akao M; Ono K; Hoshino K; Naruse Y; Takahashi K; Watanabe H; Kita T; Kimura T
    Circ J; 2009 Aug; 73(8):1498-503. PubMed ID: 19531897
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Genetic variants in ABCB1 and CYP2C19 and cardiovascular outcomes after treatment with clopidogrel and prasugrel in the TRITON-TIMI 38 trial: a pharmacogenetic analysis.
    Mega JL; Close SL; Wiviott SD; Shen L; Walker JR; Simon T; Antman EM; Braunwald E; Sabatine MS
    Lancet; 2010 Oct; 376(9749):1312-9. PubMed ID: 20801494
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cytochrome P450 2C19 polymorphism is associated with reduced clopidogrel response in cerebrovascular disease.
    Lee JB; Lee KA; Lee KY
    Yonsei Med J; 2011 Sep; 52(5):734-8. PubMed ID: 21786436
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Impact of CYP2C19 genotypes on antiplatelet therapy among Chinese patients with acute myocardial infarction after percutaneous coronary intervention].
    Xu JJ; Tang XF; Song Y; Xu N; Yao Y; Wu Y; Zhang J; Gao Z; Chen J; Gao RL; Yang YJ; Yuan JQ
    Zhonghua Xin Xue Guan Bing Za Zhi; 2017 Feb; 45(2):116-120. PubMed ID: 28260316
    [No Abstract]   [Full Text] [Related]  

  • 39. Cytochrome P-450 polymorphisms and response to clopidogrel.
    Taubert D; Bouman HJ; van Werkum JW
    N Engl J Med; 2009 May; 360(21):2249-50; author reply 2251. PubMed ID: 19458375
    [No Abstract]   [Full Text] [Related]  

  • 40. CYP2C19 genotype and early ischemic lesion recurrence in stroke patients treated with clopidogrel.
    Jeong TD; Kim SM; Kim HJ; Lee W; Kwon SU; Min WK; Kang DW; Chun S
    J Stroke Cerebrovasc Dis; 2015 Feb; 24(2):440-6. PubMed ID: 25529343
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.